Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 07, 2020

SELL
$2.51 - $6.87 $2,015 - $5,516
-803 Closed
0 $0
Q1 2020

May 04, 2020

SELL
$1.71 - $5.87 $30 - $105
-18 Reduced 2.19%
803 $3,000
Q4 2019

Feb 04, 2020

SELL
$2.78 - $4.7 $458 - $775
-165 Reduced 16.73%
821 $4,000
Q3 2019

Nov 12, 2019

BUY
$4.2 - $7.79 $4,141 - $7,680
986 New
986 $4,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $247M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.